Insider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $70,081.02 in Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 2,801 shares of the company’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $25.02, for a total value of $70,081.02. Following the transaction, the chief executive officer now directly owns 6,388 shares in the company, valued at $159,827.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jacob Chacko also recently made the following trade(s):

  • On Wednesday, September 15th, Jacob Chacko sold 3,736 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $25.06, for a total value of $93,624.16.
  • On Friday, September 10th, Jacob Chacko sold 2,942 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $25.08, for a total value of $73,785.36.
  • On Tuesday, September 7th, Jacob Chacko sold 5,981 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $25.11, for a total transaction of $150,182.91.

NASDAQ:ORIC opened at $24.57 on Friday. ORIC Pharmaceuticals, Inc. has a one year low of $15.67 and a one year high of $40.81. The firm has a market cap of $966.04 million, a price-to-earnings ratio of -9.10 and a beta of 2.91. The firm’s fifty day moving average is $19.80 and its two-hundred day moving average is $22.22.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, August 10th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, research analysts predict that ORIC Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

A number of large investors have recently bought and sold shares of ORIC. Cubist Systematic Strategies LLC purchased a new stake in shares of ORIC Pharmaceuticals during the 1st quarter worth about $33,000. Great West Life Assurance Co. Can boosted its stake in shares of ORIC Pharmaceuticals by 133.8% during the 1st quarter. Great West Life Assurance Co. Can now owns 1,440 shares of the company’s stock worth $35,000 after acquiring an additional 824 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of ORIC Pharmaceuticals during the 2nd quarter worth about $27,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of ORIC Pharmaceuticals during the 1st quarter worth about $40,000. Finally, Royal Bank of Canada boosted its stake in shares of ORIC Pharmaceuticals by 291.2% during the 1st quarter. Royal Bank of Canada now owns 1,991 shares of the company’s stock worth $49,000 after acquiring an additional 1,482 shares in the last quarter. 91.96% of the stock is currently owned by institutional investors.

ORIC has been the topic of a number of research analyst reports. Citigroup raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating in a report on Tuesday, July 6th. raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price objective on the stock in a report on Tuesday, July 6th. HC Wainwright dropped their price objective on shares of ORIC Pharmaceuticals from $54.00 to $53.00 and set a “buy” rating on the stock in a report on Wednesday, August 11th. Zacks Investment Research lowered shares of ORIC Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price objective on the stock in a report on Tuesday, July 6th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, ORIC Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $37.00.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

Further Reading: Strike Price

Insider Buying and Selling by Quarter for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.